NFKB1 and B-cell chronic lymphocytic leukemia: Considering the above and the downregulation of the NF-κB p65 phosphorylation, as a result of calcitriol supplementation, that we show here, it is not unreasonable to argue that calcitriol could act as a potential PI3K/AKT inhibitor in CLL.